Jason Cathelyn

Jason is the Head of Intellectual Property of Disc Medicine. Previously, Jason was Vice President of Intellectual Property at Acceleron Pharma, where he led intellectual property strategy development and worldwide implementation for the company’s commercial, clinical-stage, and pre-development programs. In particular, he led or supported a wide range of legal matters including patent strategy for Reblozyl®️ (luspatercept-aamt) and sotatercept (currently in development by Merck & Co. for treatment of pulmonary hypertension), building the company’s IP intellectual property team, and the successful acquisition of the company by Merck. Prior to Acceleron, Jason worked at the law firm of Ropes & Gray, where he helped clients in the biotechnology and pharmaceutical industries on a wide range of intellectual property issues, including patent portfolio development, life-cycle management, patent prosecution, patent listing and delisting matters, patent term restoration, patent litigation, and assessments regarding patentability, validity, non-infringement, and freedom-to-operate.

He received a Ph.D. in Molecular Microbiology & Microbial Pathogenesis from Washington University in St. Louis.